Brief: Mabion Updates Strategy For 2025-2030
17/11/2025 13:32
Nov 17 (Reuters) - Mabion SA MABP.WA: ADOPTS NEW STRATEGY FOR 2025-2030 REVISED 2025-2030 STRATEGY AIMS FOR 2030 SALES REVENUE 1.5 TIMES HIGHER THAN 2021-2025 AVERAGE, WITH EBITDA MARGIN OVER 30% UNDER STRATEGY PLANS TO INCREASE TOTAL DRUG SUBSTANCE PRODUCTION CAPACITY BY 40-50% TARGETS INCREASING OVERALL EQUIPMENT EFFECTIVENESS AND REDUCING KEY PROCESS TIMES BY 20% AIMS TO REACH EBITDA BREAK-EVEN POINT BY END OF 2026 TO EXPAND OPERATIONS INTO FAST-GROWING MARKETS, INCLUDING MENA REGION AND ASIA Source text: ID:nEM6gD3kma Further company coverage: MABP.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys